Case Study: Merck achieves reduced site burden and faster oncology trial enrollment with OneStudyTeam's StudyTeam

Merck Reduces Site Burden to Enroll Oncology Trials with StudyTeam

Merck, a global biopharmaceutical leader with a large oncology pipeline, faced chronic site burdens that impede patient enrollment in cancer trials — fewer than 5% of adult cancer patients enroll despite high eligibility acceptance. To ease administrative load, improve pre-screening and visit coordination, and become a sponsor of choice, Merck partnered with OneStudyTeam to deploy the StudyTeam platform at its research sites.

OneStudyTeam’s StudyTeam platform streamlined site workflows by enabling in-system pre-screening (via uploaded inclusion/exclusion criteria), real-time enrollment tracking, and automated visit and imaging management. The solution let Merck monitor enrollment speed and adjust protocols to accelerate timelines; 88% of Merck sites chose StudyTeam after a demo and 93% of those sites reused it on subsequent Merck studies, and the partnership is now scaling across Merck’s global oncology portfolio in 41 countries — markedly reducing manual spreadsheets and site burden.

Merck